Pierre Lapalme Net Worth

The estimated Net Worth of Pierre Lapalme is at least $4.48 Milion dollars as of 3 March 2015. Pierre Lapalme owns over 20,000 units of Biomarin Pharmaceutical stock worth over $4,251,717 and over the last 21 years Pierre sold BMRN stock worth over $229,619.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Pierre Lapalme BMRN stock SEC Form 4 insiders trading

Pierre has made over 11 trades of the Biomarin Pharmaceutical stock since 2006, according to the Form 4 filled with the SEC. Most recently Pierre exercised 20,000 units of BMRN stock worth $284,800 on 3 March 2015.

The largest trade Pierre's ever made was exercising 29,900 units of Biomarin Pharmaceutical stock on 26 February 2013 worth over $306,774. On average, Pierre trades about 3,575 units every 100 days since 2004. As of 3 March 2015 Pierre still owns at least 50,150 units of Biomarin Pharmaceutical stock.

You can see the complete history of Pierre Lapalme stock trades at the bottom of the page.

What's Pierre Lapalme's mailing address?

Pierre's mailing address filed with the SEC is C/O INSYS THERAPEUTICS, INC., 444 SOUTH ELLIS STREET, CHANDLER, AZ, 85224.

Insiders trading at Biomarin Pharmaceutical

Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.

What does Biomarin Pharmaceutical do?

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment

Complete history of Pierre Lapalme stock trades at Biomarin Pharmaceutical

Biomarin Pharmaceutical executives and stock owners

Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:

• Jean-Jacques Bienaime,
  Chairman of the Board, Chief Executive Officer
• Henry Fuchs,
  President - Worldwide Research & Development
• Jeff Ajer,
  Executive Vice President, Chief Commercial Officer
• Jean-Jacques Bienaime M.B.A., MBA,
  Chairman & CEO
• G. Eric Davis,
  Executive Vice President, General Counsel, Secretary
• Dr. Henry J. Fuchs,
  Pres of Worldwide R&D
• Dr. C. Greg Guyer Ph.D.,
  CTO and Exec. VP of Global Manufacturing & Technical Operations
• Jeffrey Robert Ajer,
  Exec. VP & Chief Commercial Officer
• Brian R. Mueller,
  Exec. VP of Fin. & CFO
• Richard Meier,
  Lead Independent Director
• Elaine Heron,
  Independent Director
• Robert Hombach,
  Independent Director
• Alan Lewis,
  Independent Director
• Michael Grey,
  Independent Director
• V. Bryan Lawlis,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Slamon,
  Independent Director
• Willard Dere,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Lon Cardon,
  Chief Scientific Strategy Officer
• Andrea Acosta,
  Chief Accounting Officer, Group Vice President
• C. Greg Guyer,
  Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations
• Brian Mueller,
  Chief Financial Officer, Executive Vice President
• Dr. Brinda Balakrishnan M.D., Ph.D.,
  Group VP of Corp. & Bus. Devel.
• Philip Lo Scalzo,
  Sr. VP & Chief Compliance Officer
• George Eric Davis,
  Exec. VP, Gen. Counsel & Sec.
• Traci McCarty,
  VP of Investor Relations
• Andrea L. Acosta,
  Group VP & Chief Accounting Officer
• Daniel K Spiegelman,
  EVP, Chief Financial Officer
• Athena Countouriotis,
  Director
• Mark J Enyedy,
  Director
• Barbara W. Bodem,
  Director
• Robert Baffi,
  President, Global Mfg/Tech Ops
• Cristin Hubbard,
  EVP, Chief Commercial Officer
• Kathryn E Falberg,
  Director
• William D Young,
  Director
• Pierre Lapalme,
  Director
• Jeffrey Landau,
  Sr. Vice President, Admin.
• Gwynn Williams,
  Director
• Steve Aselage,
  SVP, Global Commercial Ops
• Christopher M Starr,
  Sr. VP, Scientific Operations
• Franz L Cristiani,
  Director
• Jeffrey H Cooper,
  Chief Financial Officer
• Joseph Iii Klein,
  Director
• Emil D Kakkis,
  SVP, Business Operations
• Kenneth Bate,
  Director
• Mark Wood,
  VP, Human Resources
• John Urquhart,
  Director
• Erich Sager,
  Director
• Stuart J Swiedler,
  SVP, Clinical Affairs
• Fredric D Price,
  Chief Executive Officer
• Vijay B Samant,
  Director
• Maykin Ho,
  Director
• Mark J Alles,
  Director
• Erin Burkhart,
  GVP, Chief Accounting Officer
• Alexander Hardy,
  Chief Executive Officer